CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy

Overview

Journal Neurotherapeutics

Specialty Neurology

Date 2022 Feb 15

PMID 35165856

Authors

Cedric Happi Mbakam

Gabriel Lamothe

Guillaume Tremblay

Jacques P Tremblay

Affiliations

Soon will be listed here.

Abstract

Discovery of the CRISPR-Cas (clustered regularly interspaced short palindromic repeat, CRISPR-associated) system a decade ago has opened new possibilities in the field of precision medicine. CRISPR-Cas was initially identified in bacteria and archaea to play a protective role against foreign genetic elements during viral infections. The application of this technique for the correction of different mutations found in the Duchenne muscular dystrophy (DMD) gene led to the development of several potential therapeutic approaches for DMD patients. The mutations responsible for Duchenne muscular dystrophy mainly include exon deletions (70% of patients) and point mutations (about 30% of patients). The CRISPR-Cas 9 technology is becoming increasingly precise and is acquiring diverse functions through novel innovations such as base editing and prime editing. However, questions remain about its translation to the clinic. Current research addressing off-target editing, efficient muscle-specific delivery, immune response to nucleases, and vector challenges may eventually lead to the clinical use of the CRISPR-Cas9 technology. In this review, we present recent CRISPR-Cas9 strategies to restore dystrophin expression in vitro and in animal models of DMD.

Citing Articles

Identification of two previously unreported Duchenne muscular dystrophy gene variants in a patient diagnosed with a dystrophinopathy: a case report.

Gerges S, Naoufal R, Mansour H J Med Case Rep. 2025; 19(1):101.

PMID: 40051007 PMC: 11887092. DOI: 10.1186/s13256-025-05135-z.

Gene therapy for genetic diseases: challenges and future directions.

Qie B, Tuo J, Chen F, Ding H, Lyu L MedComm (2020). 2025; 6(2):e70091.

PMID: 39949979 PMC: 11822459. DOI: 10.1002/mco2.70091.

Evaluation of Creatine Monohydrate Supplementation on the Gastrocnemius Muscle of Mice with Muscular Dystrophy: A Preliminary Study.

Fernandes V, Dos Santos G, Iatecola A, Buchaim D, Garcia I, Reis C Pathophysiology. 2025; 32(1.

PMID: 39846639 PMC: 11755625. DOI: 10.3390/pathophysiology32010002.

Precise template-free correction restores gene function in Tay-Sachs disease while reframing is ineffective.

Hung J, Brewer R, Elbakr L, Mollica A, Forguson G, Chan W Mol Ther Nucleic Acids. 2025; 36(1):102401.

PMID: 39759878 PMC: 11699244. DOI: 10.1016/j.omtn.2024.102401.

Developing Advanced Chimeric Cell Therapy for Duchenne Muscular Dystrophy.

Budzynska K, Bozyk K, Jarosinska K, Ziemiecka A, Siemionow K, Siemionow M Int J Mol Sci. 2024; 25(20).

PMID: 39456730 PMC: 11507628. DOI: 10.3390/ijms252010947.

References

Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A . Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol. 1987; 169(12):5429-33. PMC: 213968. DOI: 10.1128/jb.169.12.5429-5433.1987. View

Jansen R, van Embden J, Gaastra W, Schouls L . Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol. 2002; 43(6):1565-75. DOI: 10.1046/j.1365-2958.2002.02839.x. View

Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S . CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007; 315(5819):1709-12. DOI: 10.1126/science.1138140. View

Bolotin A, Quinquis B, Sorokin A, Ehrlich S . Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology (Reading). 2005; 151(Pt 8):2551-2561. DOI: 10.1099/mic.0.28048-0. View

Pourcel C, Salvignol G, Vergnaud G . CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. Microbiology (Reading). 2005; 151(Pt 3):653-663. DOI: 10.1099/mic.0.27437-0. View

Makarova K, Aravind L, Wolf Y, Koonin E . Unification of Cas protein families and a simple scenario for the origin and evolution of CRISPR-Cas systems. Biol Direct. 2011; 6:38. PMC: 3150331. DOI: 10.1186/1745-6150-6-38. View

Hille F, Richter H, Wong S, Bratovic M, Ressel S, Charpentier E . The Biology of CRISPR-Cas: Backward and Forward. Cell. 2018; 172(6):1239-1259. DOI: 10.1016/j.cell.2017.11.032. View

Makarova K, Wolf Y, Iranzo J, Shmakov S, Alkhnbashi O, Brouns S . Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants. Nat Rev Microbiol. 2019; 18(2):67-83. PMC: 8905525. DOI: 10.1038/s41579-019-0299-x. View

Jiang W, Marraffini L . CRISPR-Cas: New Tools for Genetic Manipulations from Bacterial Immunity Systems. Annu Rev Microbiol. 2015; 69:209-28. DOI: 10.1146/annurev-micro-091014-104441. View

10.

Bikard D, Euler C, Jiang W, Nussenzweig P, Goldberg G, Duportet X . Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol. 2014; 32(11):1146-50. PMC: 4317352. DOI: 10.1038/nbt.3043. View

11.

Citorik R, Mimee M, Lu T . Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol. 2014; 32(11):1141-5. PMC: 4237163. DOI: 10.1038/nbt.3011. View

12.

Gomaa A, Klumpe H, Luo M, Selle K, Barrangou R, Beisel C . Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems. mBio. 2014; 5(1):e00928-13. PMC: 3903277. DOI: 10.1128/mBio.00928-13. View

13.

Zhang B . CRISPR/Cas gene therapy. J Cell Physiol. 2020; 236(4):2459-2481. DOI: 10.1002/jcp.30064. View

14.

Chylinski K, Le Rhun A, Charpentier E . The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems. RNA Biol. 2013; 10(5):726-37. PMC: 3737331. DOI: 10.4161/rna.24321. View

15.

Jinek M, Jiang F, Taylor D, Sternberg S, Kaya E, Ma E . Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. Science. 2014; 343(6176):1247997. PMC: 4184034. DOI: 10.1126/science.1247997. View

16.

Nishimasu H, Ran F, Hsu P, Konermann S, Shehata S, Dohmae N . Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell. 2014; 156(5):935-49. PMC: 4139937. DOI: 10.1016/j.cell.2014.02.001. View

17.

Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna J, Charpentier E . A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012; 337(6096):816-21. PMC: 6286148. DOI: 10.1126/science.1225829. View

18.

Wang J, Li J, Zhao H, Sheng G, Wang M, Yin M . Structural and Mechanistic Basis of PAM-Dependent Spacer Acquisition in CRISPR-Cas Systems. Cell. 2015; 163(4):840-53. DOI: 10.1016/j.cell.2015.10.008. View

19.

Ishida K, Gee P, Hotta A . Minimizing off-Target Mutagenesis Risks Caused by Programmable Nucleases. Int J Mol Sci. 2015; 16(10):24751-71. PMC: 4632775. DOI: 10.3390/ijms161024751. View

20.

Sinkunas T, Gasiunas G, Fremaux C, Barrangou R, Horvath P, Siksnys V . Cas3 is a single-stranded DNA nuclease and ATP-dependent helicase in the CRISPR/Cas immune system. EMBO J. 2011; 30(7):1335-42. PMC: 3094125. DOI: 10.1038/emboj.2011.41. View